临床实践中使用的肠内配方的血糖指数测定。

Determination of glycemic index of enteral formulas used in clinical practice.

机构信息

Nutrition Department, Federal University of Minas Gerais - UFMG, Belo Horizonte, Brazil.

Risoleta Tolentino Neves Hospital, Belo Horizonte, Brazil.

出版信息

Int J Food Sci Nutr. 2020 Mar;71(2):201-210. doi: 10.1080/09637486.2019.1634011. Epub 2019 Jun 27.

DOI:10.1080/09637486.2019.1634011

PMID:31244367

Abstract

Glycemic Index (GI) is a measure of carbohydrate quality and is recognised as a valid and reproducible method of classifying carbohydrate foods according to its effects on postprandial glycaemia. In this randomised crossover trial (RBR-7rjx3k) we determined the GI of nine enteral formulas, following the Food and Agriculture Organisation/World Health Organisation method. Forty healthy participants were included in the study (85% female mean age 27.1 ± 6.7 years). GI of the enteral formulas ranged from 40.5 to 85.2; four formulas had high GI (Nutrienteral 1.5, Novasource GI Control, Diamax, Isosource Soya), two intermediate GI (Fresubin 1.2 HP Fibre, Nutrison Energy Multifiber 1.5) and three low GI (Trophic 1.5, Glucerna, Novasource GC HP). The GI coefficient of variation ranged from 22.9% to 83.6%. The effect of the enteral formulas with low GI in glycemic control of patients with enteral nutrition prescription needs to be test in future studies.

摘要

血糖指数（GI）是衡量碳水化合物质量的指标，被认为是一种有效且可重复的方法，可根据碳水化合物对餐后血糖的影响对其进行分类。在这项随机交叉试验（RBR-7rjx3k）中，我们按照粮农组织/世界卫生组织的方法，确定了 9 种肠内配方的血糖指数。研究纳入了 40 名健康参与者（女性占 85%，平均年龄 27.1±6.7 岁）。肠内配方的血糖指数范围为 40.5 至 85.2；其中 4 种配方的血糖指数较高（Nutrienteral 1.5、Novasource GI Control、Diamax、Isosource Soya），2 种配方的血糖指数中等（Fresubin 1.2 HP Fibre、Nutrison Energy Multifiber 1.5），3 种配方的血糖指数较低（Trophic 1.5、Glucerna、Novasource GC HP）。血糖指数的变异系数范围为 22.9%至 83.6%。未来的研究需要测试低血糖指数肠内配方对有肠内营养处方患者血糖控制的影响。